Provided by Tiger Trade Technology Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

345.00
-6.0000-1.71%
Volume:545.42K
Turnover:187.34M
Market Cap:39.33B
PE:61.72
High:345.60
Open:341.56
Low:336.95
Close:351.00
52wk High:385.22
52wk Low:253.95
Shares:114.00M
Float Shares:80.95M
Volume Ratio:1.78
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.59
EPS(LYR):2.47
ROE:14.66%
ROA:7.46%
PB:7.60
PE(LYR):139.68

Loading ...

GUIDANCE: (ONC) BeOne Medicines Expects 2026 Revenue Range $6.3B - $6.5B, vs. FactSet Est of $6.4B

MT Newswires Live
·
May 06

Press Release: BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates

Dow Jones
·
May 06

Is It Too Late To Consider BeOne Medicines (ONC) After Its 23% One Year Gain?

Simply Wall St.
·
May 06

BeOne Medicines AG expected to post earnings of 87 cents a share - Earnings Preview

Reuters
·
May 04

BeOne Medicines Receives US FDA Priority Review for Tevimbra Combination Therapy

MT Newswires Live
·
Apr 29

Earning Preview: BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS this quarter’s revenue is expected to increase by 17.70%, and institutional views are bullish

Earnings Agent
·
Apr 29

BEIGENE Secures Global Exclusive Rights to Develop Trispecific Therapy Through Huahui Anjian Partnership

Stock News
·
Apr 27

Press Release: BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6

Dow Jones
·
Apr 22

Beigene Reports Profit Turnaround with 2025 Net Income of 1.461 Billion Yuan

Stock News
·
Apr 14

Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ), BeOne Medicines (ONC) and Helus Pharma (HELP)

TIPRANKS
·
Apr 13

BeOne Medicines (ONC) Receives a Buy from Truist Financial

TIPRANKS
·
Apr 10

OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease

prnewswire
·
Apr 09

RBC Capital Keeps Their Buy Rating on BeOne Medicines (ONC)

TIPRANKS
·
Apr 09

BEIGENE Grants 17,700 Restricted Stock Units in Form of ADSs

Stock News
·
Apr 08

Truist Financial Remains a Buy on BeOne Medicines (ONC)

TIPRANKS
·
Apr 06

Is BeOne Medicines (ONC) Pricing In Too Much Optimism After Recent Share Price Drop?

Simply Wall St.
·
Mar 25

Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)

TIPRANKS
·
Mar 18

Early Cancer Drug Trial Termination Highlights Pipeline Risk for BeOne Medicines (ONC)

TIPRANKS
·
Mar 17

BeOne Medicines Cut to Hold From Buy by Jefferies

Dow Jones
·
Mar 16

Is It Time To Reassess BeOne Medicines (ONC) After Recent Share Price Weakness

Simply Wall St.
·
Mar 15